Caricamento...
Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality
Dyslipidemia is one of the common risk factors for NAFLD and is associated with cardiovascular (CV) mortality, which is the most common cause of death in NAFLD. Lipid‐lowering agents (LLAs) are used to reduce CV events in the general population. Our aim was to assess whether the use of LLAs in patie...
Salvato in:
| Pubblicato in: | Hepatol Commun |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6167074/ https://ncbi.nlm.nih.gov/pubmed/30288477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1241 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|